DigestRedComo funciona
Red
/
Empresas
En
No verificado

Enanta Pharmaceuticals, Inc.

Sobre qué escribimos

BiotecnologíaFarmacéuticaMedicina - VariosSaludVIH, SIDA y enfermedades autoinmunes

33 Comunicados de prensa

Ver todos los comunicados de prensa
17/11/2025
Mercado de valores
Salud
VIH, SIDA y enfermedades autoinmunes
Biotecnología
Medicina - Varios
Farmacéutica
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2025
Fuente
Enanta Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0
04/11/2025
Eventos
Web y redes sociales
Biotecnología
Farmacéutica
Salud
Medicina - Varios
Enanta Pharmaceuticals to Participate in Upcoming Investor Conferences
Fuente
Enanta Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0
20/10/2025
Salud
VIH, SIDA y enfermedades autoinmunes
Biotecnología
Sanidad
Medicina - Varios
Farmacéutica
Eventos
Enanta Pharmaceuticals Presents New Data for Zelicapavir, its N-Protein Inhibitor, and EDP-323, its L-Protein Inhibitor, Both in Development for the Treatment of Respiratory Syncytial Virus (RSV) at IDWeek™ 2025
Fuente
Enanta Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0
07/10/2025
Ciencia
Biotecnología
Farmacéutica
Salud
VIH, SIDA y enfermedades autoinmunes
Sanidad
Eventos
Industria
Enanta Pharmaceuticals to Present Data for Zelicapavir and EDP-323, Two Candidates in Development for the Treatment of Respiratory Syncytial Virus (RSV) at IDWeek™ 2025
Fuente
Enanta Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0
02/10/2025
Ciencia
Biotecnología
Farmacéutica
Finanzas
Salud
Asociaciones/Profesionales
Medicina - Varios
Enanta Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Fuente
Enanta Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0
01/10/2025
Ciencia
Biotecnología
Farmacéutica
Finanzas
Salud
Asociaciones/Profesionales
Medicina - Varios
Enanta Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock
Fuente
Enanta Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0
30/09/2025
Asociaciones/Profesionales
Salud
VIH, SIDA y enfermedades autoinmunes
Biotecnología
Finanzas
Farmacéutica
Enanta Pharmaceuticals Announces Proposed Public Offering of Common Stock
Fuente
Enanta Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0
29/09/2025
Salud
VIH, SIDA y enfermedades autoinmunes
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Web y redes sociales
Telefonía
Industria
Enanta Pharmaceuticals Reports Positive Topline Results from its Phase 2b Study of Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV) in High-Risk Adults
Fuente
Enanta Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0
26/09/2025
Web y redes sociales
Telefonía
Industria
Biotecnología
Farmacéutica
Salud
Medicina - Varios
Enanta Pharmaceuticals to Present Topline Results from its Phase 2b Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV) in High-Risk Adults
Fuente
Enanta Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0
03/09/2025
Salud
VIH, SIDA y enfermedades autoinmunes
Ciencia
Farmacéutica
Mercado laboral
Enanta Pharmaceuticals Announces the Passing of its Beloved and Respected Longtime Chief Financial and Administrative Officer Paul J. Mellett Jr.
Fuente
Enanta Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0